The Life Innovation Policy of Japan and Activities of MEXT
|
|
- Myles Powers
- 5 years ago
- Views:
Transcription
1 The Life Innovation Policy of Japan and Activities of MEXT November 2011 Hiroyuki KAMAI Deputy Director, Life Sciences Division Research Promotion Bureau Ministry of Education, Culture, Sports, Science and Technology (MEXT) Tokyo Japan
2 Current trends of Policies for Life Sciences in Japan 2 The 2 nd S&T Basic Plan (FY2001-FY2005) The Government decided 4 strategic areas including Life Sciences The 3 rd S&T Basic Plan (FY2006-FY2010) The Government decided 4 priority fields to be promoted including Life Sciences New Growth Strategy (June 2010, Cabinet Decision) The Government decided 7 strategic areas including Life Innovation (innovation in the medical and nursing care sectors) The 4 th S&T Basic Plan (FY2011-FY2015) The Government regards Life Innovation as the priority agenda which should be addressed.
3 The New Growth Strategy: Blueprint for Revitalizing Japan June 18, 2010 Cabinet Decision Targets 2020 Achieve nominal & real growth in excess of 3% and 2%. Return consumer prices to positive increase in FY2011. Lower the unemployment rate to 3% - 4% at an early time Sluggish growth (real growth rate at 1% in the past decade; potential growth rate at 1%) Trapped in deflation (consumer price increase rate at 0% in the past 20 years) Unemployment rate at 5% 7 Strategic Areas & 21 National Strategic Projects Green Innovation Science-andtechnology IT oriented nation Employment & human resources Financial sector Life Science Innovation Tourism-oriented nation & local revitalization Asia Creation of New Demand and Jobs (Third Approach) Area Environment (Green Innovation) Health (Life Science Innovation) Demand Creation 50 trillion 50 trillion Asia 12 trillion Tourism 11 trillion Job Creation 1.4 million jobs 2.84 million jobs 0.19 million jobs 0.56 million jobs 3
4 The 4 th S&T Basic Plan (FY ) 2015) The Forth Science and Technology Basic Plan (FY ) (approved by the Cabinet, August 2011) Realization of Sustainable Growth and Societal Development into the Future : Reconstruction and revival from the disaster Promoting Green and Life Innovation System reforms directed at promoting STI The Basic Plan specifies several areas below as Strategic Prioritized issues in life sciences field Development of revolutionary disease prevention methods Development of new early diagnoses methods Realization of safe and highly effective medial treatment Improvement of Quality of life (QOL) for the sick, elderly, and disabled 4
5 Life Innovation Acceleration Initiative (MEXT) Budget proposal for FY 23: 10 billion yen To keep our society healthy and to sustain our economy continuously growth -- acceleration of R&Ds for unmet medical needs and Regenerative Medicine ACTION:Establish trans-ministerial consistent support system (Regenerative Medicine Highway) 4.7 billion yen - Consistently support the research of stem-cells such as ips cells from basic to clinical research by the cooperation with relevant ministries concerned. -Promote systems biology (unite of life sciences and mathematical principle calculation science) that is the current of research in the world, and generate a technical system that contributes the achievement of regenerative medicine by the network. Cancer Medicine seeds ACTION:Promote world leading innovative cancer researches to the medicine. 3.6 billion yen - Promote world leading innovative cancer researches and accelerate researches aim at the clinical application. Neural and Mental Diseases Medicine ACTION:Overcome neural and mental diseases by brain science research. 1.8 billion yen - Achieve early diagnosis and treatment by clarify the mechanism. Immunological and Allergy Diseases Medicine ACTION:Establish safety and effectiveness of pollenosis vaccine. 0.3 billion yen - Put research progress pollenosis vaccine into practical use by establishing safety and effectiveness. Basic research Innovative seeds ips cells Contribute to growth by overcoming the diseases. The market of over 10 trillion yen scale is expected in the world Create the market of several hundred billion yen scale per one goods by producing a innovative cancer medicine Clinical research Contribute to the social rehabilitation of about 2.7 million depression and dementias patients Contribute to return-towork and improvement of productivity of about 17 million or more pollenosis patients 5
6 Focusing of S&T Budgets Request (FY2012) 6 Promotion of Life Innovation: 122 billion Yen Focusing on the activities to create life innovation which aims to -overcome incurable diseases and -realizing a society with healthy bodies and minds through effective use of our leading research fields and unique methodologies.
7 Life Science Project in Japan(1) The research and development of the field of life Science based on social needs A realization project of the regenerative medicine -promote the ips/es cell researches strategically by the All Japan system to survive successfully international competition. Strategic Research program for Brain Science -strategically promote brain science and research that aims at passing and returning the benefits of research results to society as a whole. Research Project for Innovative Cancer Medicine Development -promote the development of advanced cancer medicine by fostering results of basic and clinical researches on cancer into the innovative seeds for translational and clinical cancer researches. Platform for Medical and Pharmaceutical Research -enhance supporting platform for medical and pharmaceutical research for innovative drug development. -construct an interdisciplinary research center (experimental and theoretical approaches) for innovative drug development. Accelerated Networking Program for Translational Research -construct supporting centers for translational research, which lead hopeful outcomes of fundamental researches to bedside. 7
8 Life Science Project in Japan(2) Reconstruction and revival from the disaster Tohoku Medical-Megabank Plan -conduct genome-cohort studies in afflicted areas to secure medical experts and realize personalized-medicine for local residents, that results in recovery and rehabilitation of damaged local medical system. System maintenance to support the whole life science research National Bio Resources Project -establish the highest quality bio-resources and its supply system at a world-class level to promote life science researches Integrated Life Science Database Project -improve the convenience of Database in Life Science and construct base for supporting world top-level researches 8
9 The Project for Realization of Regenerative Medicine (1)iPS cell research core institute (1)Kyoto Univ. Prof. Yamanaka Basic research of ips cells Evaluation technology of ips cell RIKEN Sasai group director Operational technology of ips Cell Development of Treatment for visual impairments MEXT Strategic Working Group for Stem cell Research and Regenerative medicine Executive steering committee with Program Director and Officer (3) Development Area of operational technology of Stem Cells Realization of Regenerative Medicine Evaluation committee (2)Stem Cell Bank for Research MEXT ips Cell Research Network (1) Keio Univ. Prof. Okano Focus on central nerve system Development of Treatment for spinal cord injury (4) Development Area of Stem Cells Treatment (1) (1) (attachment) Tokyo Univ. Prof. Nakauch Focus on Blood cells like platelet and red blood cell
10 Road Map for ips Cell Research by MEXT Goal 1 Basic Research Elucidation of the molecular mechanism of initialization of ips cells [Within 5 years] Establishment of new pluripotent stem cells different from ips cells [Within 5 years] (attachment) Goal 2 Standardization Identification of evaluation items for clarifying the characteristics of ips cells Comparison of the characteristics of ips cells established through various protocols [In the next 1 year] Establishment and optimization of the qualified ips cells with low risk Establishment of evaluation method of ips cells Construct of accumulation/analyses framework for systematic evaluation of ips cells [In the next two years] Construct of the system to supply ips cells with high quality and low risk in Japan and abroad [In the next 3 years] Distribution of ips cells with high quality and low risk in Japan and abroad, under low cost and the same conditions [After 3 years] Identification of diseases for efficient establishment of disease-specific ips cells Technological training on ips cells for clinical researchers Industrial applications of toxicity assessment system useful for drug discovery [In progress] Goal 3 ips cells for research of the diseases / drug discovery Establishment and optimization of the preparation protocol of ips cells for disease research Establish the evaluation method of ips cells for disease research Systematic banking of disease-specific ips cells [Within 2 years] Distribution of disease-specific ips cells to researchers in Japan and abroad [After 2 years] Reproduction and elucidation of pathological conditions using ips cells originated from patients with congenital diseases Reproduction and elucidation of pathological conditions using ips cells originated from patients with acquired diseases [Future 5 to 10 years] Goal 4 Regenerative medicine Central nervous system Cornea Retinal pigment epithelial cell Photoreceptor cell Platelet Erythrocyte Hematopoietic stem cell Cardiac muscle Osteogenic cell and cartilage Skeletal muscle Endodermal cell ips cell bank for regenerative medicine Basic research [differentiation induction/purification] Pre-clinical research Basic research [differentiation induction/purification] Pre-clinical research Basic research/pre-clinical research Basic research [differentiation induction/purification] / Pre-clinical research Basic research [differentiation induction/purification] / Pre-clinical research Basic research [differentiation induction/purification] Basic research [differentiation induction/purification] / Pre-clinical research Pre-clinical research Basic research [differentiation induction/purification] Pre-clinical research Basic research [differentiation induction/purification] Pre-clinical research Basic research [differentiation induction/purification] Pre-clinical research Basic research [differentiation induction/purification] / Pre-clinical research Establishment of ips cell bank considering the application of regenerative medicine [Within 5 years] Distribution of ips cells for regenerative medicine for pre-clinical research [After 4 years] * All of descriptions are translated tentatively
Realizing the Future that Regenerative Medicine Will Open
470 Hitachi Review Vol. 65 (2016), No. 9 Featured Articles Realizing the Future that Regenerative Medicine Will Open Shizu Takeda, Ph.D. OVERVIEW: Regenerative medicine is an innovative approach to medicine
More informationResearch area in the Strategic Objective Development of optical control technologies and elucidation of biological mechanisms
Research area in the Strategic Objective Development of optical control technologies and elucidation of biological mechanisms 6.1.5 Development and application of optical technology for spatiotemporal
More informationRecent Progress in ips Cell Research and Application
Recent Progress in ips Cell Research and Application Shinya Yamanaka, M.D., Ph.D. Center for ips Cell Research and Application (CiRA), Kyoto University, Japan Takeda - CiRA Joint Program, Shonan, Japan
More informationFederal Funding for Brain Research. Congressional Support Accelerates Discovery
The American Brain Coalition (ABC) is a non-profit organization that brings together people with disabling brain disorders, the families of those that are affected, and the professionals who research and
More informationCurrent Topics of Pharmaceutical Regulatory Affairs in Japan
Pharmaceuticals and Medical Devices Agency Current Topics of Pharmaceutical Regulatory Affairs in Japan Takeyuki SATO Associate Director (International and Product Evaluation Affairs), Centre for Product
More information6. Vision 3: Leading the Japanese economy forward as a high value-added industry"
6. Vision 3: Leading the Japanese economy forward as a high value-added industry" Strategic points for realizing the vision Streamlining and rationalization R&D to create innovative drugs Proactively introducing
More informationHuman ips/es Cell Technology and Its Application to Toxicology Testing
Human ips/es Cell Technology and Its Application to Toxicology Testing -Especially focusing on in vitro cardiac function toxicity- Atsushi Sanbuissho, PhD Daiichi Sankyo Co., Ltd. Kenji Yasuda, Prof Tokyo
More informationInnovating out of Crisis
Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab
More informationRegulatory Perspectives of Japan
International Alliance for Biological Standardization (IABS) Challenge Toward Sound Scientific Regulation of Cell Therapy Products at Kyoto International Conference Center, Kyoto, Japan Regulatory Perspectives
More information2 R&D Contribution to the Recovery and Reconstruction of Businesses in Disaster-hit Area
Part I Toward a Robust and Resilient Society ~ Lessons from the Great East Japan Earthquake ~ 2 R&D Contribution to the Recovery and Reconstruction of Businesses in Disaster-hit Area The 4th Basic Plan
More informationTowards a stem cell based therapy for Parkinson s Disease
Stem cell based therapies for Parkinson s Disease Towards a stem cell based therapy for Parkinson s Disease MALIN PARMAR NYSCF Robertson Investigator Lund University, Sweden INTR, Port Douglas, Sept 13-16,
More informationINCJ to make additional investment in Megakaryon
News Release INCJ to make additional investment in Megakaryon Tokyo, March 23, 2015 Innovation Network Corporation of Japan ( INCJ ) announced today a decision to make an additional investment of up to
More informationComprehensive Collaboration Agreement between Osaka University and Chugai ~Total of 10 billion yen contribution over 10 years to IFReC~
May 19, 2016 National University Corporation Osaka University Comprehensive Collaboration Agreement between Osaka University and Chugai ~Total of 10 billion yen contribution over 10 years to IFReC~ Outline
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationEducation Critical to Stem Cell Therapy Pipeline
June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California
More informationA bold vision for 2025
Leading the Biomedical Revolution in Precision Health: How Stanford Medicine is Developing the Next Generation of Health Annual Stanford Medicine Population Health Sciences Colloquium October 26, 2015
More informationThe Role of Adult Stem Cells in Personalized and Regenerative Medicine
The Role of Adult Stem Cells in Personalized and Regenerative Medicine Christopher J. Neill, Director of Corporate Operations American CryoStem Corporation Objective To illustrate the potential benefits
More information5-Year Strategy for the Creation of Innovative Pharmaceuticals and Medical Devices
5-Year Strategy for the Creation of Innovative Pharmaceuticals and Medical Devices April 26, 2007 Ministry of Education, Culture, Sports, Science and Technology (MEXT) Ministry of Health, Labour and Welfare
More informationThe Plan for Promotion of Medical Research and Development
Provisional The Plan for Promotion of Medical Research and Development Approved by the Headquarters for Healthcare Policy July 22, 2014 Partially Revised February 17, 2017 Table of Contents Introduction...
More informationSeptember 2016 Minister of Education, Culture, Sports, Science and Technology
Evaluation of Operating Results for Japan Science and Technology Agency Estimated at the Completion of the Third Period for Medium to Long-Term Objectives September 016 Minister of Education, Culture,
More informationNIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts)
NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts) 1. NCI (National Cancer Institute) cancer cause, prevention, detection, diagnosis, treatment and control 2. NIAID
More informationPromoting collaboration: Strategies and programs within health research and innovation
Promoting collaboration: Strategies and programs within health research and innovation Anne K Fahlvik, PhD, Executive director Mari K Nes, PhD, Special Adviser The Research Council of Norway The Research
More informationFY2017 to FY2019 Medium-Term Management Plan. March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda
FY2017 to FY2019 Medium-Term Management Plan March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda Contents I. Review of the Previous Plan p.1-4 II. Overview of the New Medium-Term Management
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hase T, Tsuji S, Shimokawa K, Tanaka H Tohoku Medical Megabank Organization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure
More informationINUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR > SOLUTIONS AND HOPE Millions of people worldwide suffer from deadly diseases, chronic conditions and congenital disorders
More informationWider Adoption of Regenerative Medicine Driven by Open Innovation
Review Vol. 64 (2016), No. 10 693 Featured Articles Wider Adoption of Regenerative Medicine Driven by Open Innovation Kohin Shu, Ph.D., Engineering Masaharu Kiyama Takayuki Nozaki, Ph.D., Medical Science
More informationMolecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics
Molecular Medicine Molecular Medicine Stem cell therapy Gene therapy Tumor therapy Immunotherapy Other therapies Vaccines Genetic diagnostics Medical genomics Medication Diagnostics medicine: old desire
More informationResearch collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017
Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao 1 29 th November, 2017 Collaboration with Q therapeutics to develop new ipsc therapies for CNS diseases REPROCELL announced a
More informationEvaluation of Operating Results for National Institute of Radiological Sciences Estimated at the End of the Third Medium to Long-Term Objective Period
Evaluation of Operating Results for National Institute of Radiological Sciences Estimated at the End of the Third Medium to Long-Term Objective Period September 2015 Minister of Education, Culture, Sports,
More informationAlliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd.
Alliance for Japanese market - ips cell technology into practical use - Healios K.K. Dainippon Sumitomo Pharma, Co., Ltd. December 2, 2013 Background March 28, 2013 Capital alliance: DSP took a 1.5billion
More informationStem Cells: Introduction and Prospects in Regenerative Medicine.
Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,
More informationCentre for NanoHealth
Steve Conlan PhD An integrated collaborative base for businesses in Wales Director - Reproductive Biology & Cancer Research Institute of Life Science School of Medicine Unique interdisciplinary R&D environment,
More informationFuture Challenges in Fujitsu s Healthcare Business Activities of Next-Generation Healthcare Innovation Center
Future Challenges in Fujitsu s Healthcare Business Activities of Next-Generation Healthcare Innovation Center Naoki Nakano Masakazu Shimomura Since the mid-1970s, Fujitsu has been at the forefront of information
More informationSuccessful Academia-Pharma Collaboration Drug Discovery and Clinical Development
Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development Toshio MIYATA Tohoku University Graduate School of Medicine United Centers for Advanced Research and Translational Medicine
More information2. Purpose and Mission of the icems
Research Center Project Host institution name Kyoto University Head of host institution Professor Kazuo Oike, Ph. D., President of Kyoto University Title of center project Center name Institute for Integrated
More informationHarvard Stem Cell Institute
Welcome to the Harvard Stem Cell Institute The 1000+ scientists in the HSCI network share one goal: finding cures for human diseases. We aim to: Stimulate healing in patients by harnessing the potential
More informationThe Future of Health Research: It s in Our Culture
The Future of Health Research: It s in Our Culture Pop quiz. Who was the inventor of the light bulb? Thomas Edison (1847-1931) If you answered Thomas Alva Edison, you re absolutely wrong. But don t feel
More informationE&T objectives in evolving pharma business models. Magda Chlebus Director Science Policy Brussels, 2 March 2015
E&T objectives in evolving pharma business models Magda Chlebus Director Science Policy Brussels, 2 March 2015 Education adapted to demand? Declining number of students choosing science Education still
More informationRegulatory Updates on Cellular Therapy Products in Japan
Regulatory Updates on Cellular Therapy Products in Japan Daiju Okuda, Ph.D. Principle Reviewer Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA), Japan September
More informationPer Morten Sandset Japan-UiO cooperation within health and care research status and opportunities
Per Morten Sandset p.m.sandset@medisin.uio.no Japan-UiO cooperation within health and care research status and opportunities Japan-UiO cooperation within health and care Brief presentation of the University
More informationAndrew Finnerty General Manager - CCMI
Andrew Finnerty General Manager - CCMI Manufacturing Human Mesenchymal Stem Cells for Clinical Trials Quality Considerations Biopharma and Pharma RQA Regional Forum Bioclin Laboratories, Athlone 13 May
More information8. Vision 4: Supporting to create an advanced healthcare country Creating a society where people can live long, healthy lives with peace of mind
8. Vision 4: Supporting to create an advanced healthcare country Creating a society where people can live long, healthy lives with peace of mind Strategic points for realizing the vision Creating a society
More informationJapan Update. IMDRF Open Stakeholder Forum September 2017
Japan Update IMDRF Open Stakeholder Forum September 2017 - Regulatory Authorities in Japan - MHLW Ministry of Health, Labor and Welfare PMDA Pharmaceuticals and Medical Devices Agency Final Authorization
More informationStem cells in Development
ANAT 2341 Embryology Lab 10 8 Oct 2009 Therapeutic Use of Stem Cells Practical Hurdles & Ethical Issues Stem cells in Development Blastocyst Cord blood Antonio Lee PhD Neuromuscular & Regenerative Medicine
More informationStem cells in Development
ANAT 2341 Embryology Lab 10 8 Oct 2009 Therapeutic Use of Stem Cells Practical Hurdles & Ethical Issues Stem cells in Development Blastocyst Cord blood Antonio Lee PhD Neuromuscular & Regenerative Medicine
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
More informationSection I: Pharmaceuticals and Medical Devices
SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical
More informationApplication of Deep Learning to Drug Discovery
Application of Deep Learning to Drug Discovery Hiroshi Tanaka Tohoku Medical Megabank Orga nization, Tohoku University Current Situation of Drug Discovery Rapid increase of R&D expenditure More than 1B
More informationKonica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion
News Release Konica Minolta and INCJ Agree to Acquire Ambry Genetics in a Deal Valued at US$1 billion Advances Konica Minolta strategy to establish a leadership position in precision medicine Contributes
More informationUnderstanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationInduced Stem Cells in Research and Therapy of Neuropsychiatric Disorders
Berlin-Brandenburg Center for Regenerative Therapies Induced Stem Cells in Research and Therapy of Neuropsychiatric Disorders Josef Priller Department of Neuropsychiatry Laboratory of Molecular Psychiatry
More informationPhRMA. Annual Press Conference
PhRMA Annual Press Conference February 1, 2017 Patrik Jonsson Chairman of Japan Based Executive Committee PhRMA Japanese Policy Changes Have Fostered Patients' Access to New Medicines Thanks to the transformation
More informationREMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research
REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research Charles Kessler European Commission DG Research, Health Directorate Outline of presentation Main features of
More informationMONASH BIOMEDICINE DISCOVERY INSTITUTE. At a Glance. monash.edu/discovery-institute
MONASH BIOMEDICINE INSTITUTE At a Glance monash.edu/discovery-institute MONASH BIOMEDICINE INSTITUTE WHO WE ARE An institute with the scale and scope to tackle major research questions. We are one of the
More informationRegulatory Reform for Regenerative Medicine in Japan
Pharmaceuticals and Medical Devices Agency Regulatory Reform for Regenerative Medicine in Japan Daisaku Sato, PhD. Director, Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices
More informationTHE GLOBAL MARKET FOR STEM CELLS
THE GLOBAL MARKET FOR STEM CELLS BIO035F May 2016 Paul Evers Project Analyst ISBN: 1-62296-292-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA),
More informationWorking Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017
Working Together for Better Health Partnering with Boehringer Ingelheim JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017 Welcome to Partnering with Boehringer Ingelheim Our guiding principle Value
More informationMovement Optimization System
Project Overview Using Cyber-Physical Systems (CPS) to ensure safety and tight security and create a stress-free environment environment Social Landscape / Social Agenda As society becomes increasingly
More informationSources: Tokyo Institute of Technology City of Kawasaki. For immediate release: August 4, 2017
PRESS RELEASE Sources: Tokyo Institute of Technology City of Kawasaki For immediate release: August 4, 2017 Subject line: Tokyo Institute of Technology and Kawasaki City are Combining Forces in R&D on
More informationPromising Future for Ex vivo Tissue Fabrication. Eiji Kobayashi, MD, PhD Department of Organ Fabrication, Keio University School of Medicine, Japan
Promising Future for Ex vivo Tissue Fabrication Eiji Kobayashi, MD, PhD Department of Organ Fabrication, Keio University School of Medicine, Japan The research for fabricating tissue/organs through cultivation
More informationWhat IMI means for POLAND
What IMI means for POLAND Maciej Bagiński Gdansk University of Technology Deputy of Polish Delegate to IMI SRG History of calls 1 st call 15 projects (395 teams) 281 mln 2 nd call 8 projects (193 teams)
More informationLesson 7A Specialized Cells, Stem Cells & Cellular Differentiation
Lesson 7A Specialized Cells, Stem Cells & Cellular Differentiation Learning Goals I can explain the concept of cell differentiation and cell specialization. I can explain how the cell structure relates
More informationWorld s 1 st Clinical Trial with Allogeneic ipsc-derived Therapeutic Product (Cynata Therapeutics) Physician Led Study Using ipscs for
Table of Contents SCOPE AND METHODOLOGY... 8 Market Definition... 8 Market Scope... 8 Market Stakeholders... 9 Research Methodology... 10 Secondary and Primary Research Methodology... 10 Market Size Estimation
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationRegulatory frameworks of regenerative medicines and products review in Japan
Regulatory frameworks of regenerative medicines and products review in Japan August 27th, 2018 Kenji KUROIWA Deputy Director, Medical Devices Evaluation Division Ministry of Health, Labour and Welfare,
More informationPre-consultation system at the authority for clinical trials and NDA in Japan
Pharmaceuticals and Medical Devices Agency Pre-consultation system at the authority for clinical trials and NDA in Japan Takeyuki SATO Associate Director, Centre for Product Evaluation Pharmaceuticals
More informationThe Role of Philanthropy in Medical Device Development
The Role of Philanthropy in Medical Device Development The Federal Government, through the National Institutes of Health (NIH), often shoulders major funding for initial research in the life sciences.
More informationLevel 4 Extended Diploma in Health Studies (Medical Pathway)
Level 4 Extended Diploma in Health Studies (Medical Pathway) Overview This is a 120 credit qualification. In addition to providing a sound basis for those seeking a career in the health sector, this course
More informationInnovating to Create Value through New Perspectives and Synthesis
Feature Article Innovating to Create Value through New Perspectives and Synthesis With the corporate mission of Contributing to Society through Healthcare, the Terumo Group has brought valuable innovation
More informationPMDA s Efforts - Regulation and Innovation. Takao YAMORI, Ph.D. Executive Director Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA s Efforts - Regulation and Innovation Takao YAMORI, Ph.D. Executive Director Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint
More informationThe Present State and Future Perspective of Biomedical Engineering in Japan
The Present State and Future Perspective of Biomedical Engineering in Japan Shunsuke Sato (Osaka University, Graduate School of Engineering Science) Fumihiko Kajiya (Okayama University, Graduate School
More informationDisruptive Innovation at the NIH. Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health
Disruptive Innovation at the NIH Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health NIH: Steward of Medical and Behavioral Research for the Nation Science in
More informationBME 177. Engineering stem cells. Gayatri Pal Lecturer Biomolecular Engineering
BME 177 Engineering stem cells Gayatri Pal Lecturer Biomolecular Engineering Introduction Graduated from MCD Biology (Yeast Cell Cycle) -CIRM classes (Introduction to stem cell biology) Post-doc training
More informationStem Cells Canadian Perspective
Stem Cells Canadian Perspective John Laffey Critical Illness and Injury Research Centre, Keenan Research Centre, St Michael s Hospital. Departments of Anesthesia, Physiology and Interdepartmental Division
More informationSocial Innovation 2014/ Smart City Week 2014 Oct. 29 PACIFICO Yokohama. Life Innovation and Future Health Care Systems
Social Innovation 2014/ Smart City Week 2014 Oct. 29 PACIFICO Yokohama Life Innovation and Future Health Care Systems Yokohama City University Vice president Association of Medical Science Professor (Pharmacology)
More informationTrend in diagnostic biochip. Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital Handling of the early stage is important for
More informationNew Direction of Japanese Regulations on MD/IVD. - Japan Update -
New Direction of Japanese Regulations on MD/IVD - Japan Update - Topics Collaboration plan to accelerate review of MDs Revision of Pharmaceutical Affairs Law (PAL); Implementation of PMD Act. 2 Collaboration
More informationAjinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies
Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager,
More informationRegulatory Updates on Cellular Therapy Products in Japan
Regulatory Updates on Cellular Therapy Products in Japan Tetsuya Kusakabe, Ph.D., M.P.H. Review Director Office of Cellular and Tissue-based Products Pharmaceuticals and Medical Devices Agency (PMDA),
More informationBasic Law on Suicide Countermeasures (Law No. 85 of 2006)
Basic Law on Suicide Countermeasures (Law No. 85 of 2006) Revised by the Diet, March 22, 2016 This document is translated by the Research Project Team on Suicide Prevention Policy funded by Japanese Ministry
More informationLife SCIENCE GR ADUATE SCHOOL OF
GR ADUATE SCHOOL OF Life SCIENCE Transdisciplinary Life Science Course Biosystems Science Course Biomedical and Pharmaceutical Science Course Division of Clinical Pharmacy Message from the Dean Masakane
More informationJapan Update. - Progress of measures to improve access to innovative MDs/IVDs - March, 2016
Japan Update - Progress of measures to improve access to innovative MDs/IVDs - March, 2016 Topics 1. Training center under international regulatory harmonization strategies by MHLW and PMDA 2. Designation
More informationPMDA s Future Activities
PMDA s Future Activities Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 2017 年 4 月 24 日 18:30 版 Disclaimer The views and opinions expressed in the following
More informationUNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process
IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process Genetic discovery AHC Patients Need Help! Researchers collect data on AHC patients (observation) Researchers interpret and evaluate data AHC
More informationPresenter: Teresa Holm
Slides are from Level 3 Biology Course Content Day, 7 th November 2012 Presenter: Teresa Holm Teachers are free to use these for teaching purposes with appropriate acknowledgement Human Stem cells Dr Teresa
More informationLaunching primary industry into growth orbit through promoting innovation in rural areas
Ministry of Agriculture, Forestry and Fisheries Launching primary industry into growth orbit through promoting innovation in rural areas n rural areas, there are many kinds of resources and assets such
More information2009 INVESTOR DAY. Medical. Allan Ross President Medical December 17, 2009
2009 INVESTOR DAY Medical Allan Ross President Medical December 17, 2009 Pall Life Sciences - Medical BioPharmaceuticals Medical 24% 17% 38% Energy, Water & Process Technologies 9% 12% Microelectronics
More informationEvaluation of Operating Results for Japan Sience and Technology Agency in the 3rd Mid to Long-Term Objective Period
Evaluation of Operating Results for Japan Sience and Technology Agency in the 3rd Mid to Long-Term Objective Period August 2017 Minister of Education, Culture, Sports, Science and Technology Contents Evaluation
More informationTo meet the challenge of providing safe, cost-effective medicines for the world s largest
An Executive Summary Biopharma in China: New Initiatives, New Opportunities To meet the challenge of providing safe, cost-effective medicines for the world s largest population, the government of China
More informationBayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
News Release Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing BlueRock Therapeutics is focused on breakthrough treatments
More informationTHE THERAPEUTIC REALITIES OF STEM CELLS
Ferghana Partners Group is a Life Sciences investment banking house with offices in London and New York. We specialise in creating and executing effective strategic transactions for pharmaceutical, chemical,
More information10:10-10:22. YIA-1 A study of newly established human peripheral blood monocyte-derived ips cell line used in allergy research 10:22-10:32
10:10-10:22 YIA-1 A study of newly established human peripheral blood monocyte-derived ips cell line used in allergy research 10:22-10:32 EPA-1 Integration of conventional cell viability assays- recruiting
More information8 th Regenerative Medicine and Stem Cells
8 th Regenerative Medicine and Stem Cells Theme: Light the Hope of Incurable Diseases March 19 21, 2 15 Busan, Republic of Korea Welcome Message Dear Friends and Colleagues, On behalf of the Organizing
More informationDRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES
DDin DRUG DISCOVERY INSIGHTS EVOTEC AND CELGENE ENTER INTO DRUG DISCOVERY COL- LABORATION FOR NEURODEGENE- RATIVE DISEASES Exclusive broad R&D collaboration based on Evotec s ipsc platform Mission Develop
More informationValuing Healthcare Biotechnology in Europe: EuropaBio s perspective
Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective The healthcare biotechnology sector The healthcare biotechnology sector includes bioscience based enterprises, which create and deliver
More informationTechnical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products
Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry
More informationThe New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017
The New News in Stem Cell Research Andrés Bratt-Leal, PhD 12/1/2017 Cell Therapy and Parkinson s Disease Very specific neural degeneration >50% of DA neurons are gone by diagnosis 1 million in the USA,
More informationFrom Stem Cell to Any Cell
sciencenewsforkids.org http://www.sciencenewsforkids.org/2005/10/from-stem-cell-to-any-cell-2/ From Stem Cell to Any Cell By Emily Sohn / October 11, 2005 For maybe a day, about 9 months before you were
More information